Drug intelligence / Profile preview

BT300

Development stage: Preclinical
Lead developer: BioTheraVision
Modality: Small Molecules
Administration: Ophthalmic

Overview

BT300 is a preclinical-stage ophthalmic therapeutic being developed by BioTheraVision for the treatment of post-ocular surgery inflammation. The drug is part of a strategy to repurpose known molecules for new ocular indications. While the specific active ingredient and molecular target have not been publicly disclosed, the therapy is designed to manage inflammatory responses following eye surgery. BioTheraVision is a Chicago-based pharmaceutical company focusing on innovative treatments for ocular diseases.

Beyond the preview

Go deeper on BT300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT300.

Explore the full profile